IJERPH, Vol. 18, Pages 11008: Dental Healthcare Amid the COVID-19 Pandemic

IJERPH, Vol. 18, Pages 11008: Dental Healthcare Amid the COVID-19 Pandemic International Journal of Environmental Research and Public Health doi: 10.3390/ijerph182111008 Authors: Rabia Tariq Butt Omer Sefvan Janjua Sana Mehmood Qureshi Muhammad Saad Shaikh Julia Guerrero-Gironés Francisco J. Rodríguez-Lozano Muhammad Sohail Zafar The hustle and bustle of the planet Earth have come to a halt thanks to the novel coronavirus. The virus has affected approximately 219 million people globally; taken the lives of 4.55 million patients as of September 2021; and created an ambiance of fear, social distancing, and economic instability. The purpose of this review article is to trace the historical origin and evolution of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2). The virus is highly contagious with a unique feature of rapid mutations—the scientific research is paving the way for discoveries regarding novel coronavirus disease (COVID-19) diagnosis, features, prevention, and vaccination. The connections between the coronavirus pandemic and dental practices are essential because COVID-19 is transmitted by aerosols, fomites, and respiratory droplets, which are also produced during dental procedures, putting both the patient and the dentist at risk. The main emphasis of this paper is to highlight the psychological, economic, and social impact of this pandemic on dental practices throughout the world and under what circumstances ...
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Tags: Review Source Type: research

Related Links:

NEW BRUNSWICK, N.J., DECEMBER 5, 2021 – Johnson &Johnson (NYSE: JNJ) (the Company) today announced preliminary results from an independent study, including a subset of participants from the Janssen-sponsored COV2008 study, conducted by Dan Barouch, M.D., Ph.D., et al. of Beth Israel Deaconess Medical Center (BIDMC), which showed that a booster shot of the Johnson &Johnson COVID-19 vaccine (Ad26.COV2.S), administered at six months after a two-dose primary regimen of BNT162b2, increased both antibody and T-cell responses. These results demonstrate the potential benefits of heterologous boosting (mix-and-match)....
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve as a global health crisis. Although highly effective vaccines have been developed, non-pharm...
Source: BMC Public Health - Category: Consumer Health News Authors: Tags: Study protocol Source Type: research
Rich nations are again raising barriers to ending the pandemic – politicians, globally, must follow the science and act togetherDr Ayoade Olatunbosun-Alakija is the co-chair of the African Union ’s Africa Vaccine Delivery AllianceThe advent of the Omicron variant has given us a glimpse of an alternative future in which, had the Sars-CoV-2 virus been initially identified in Africa in early 2020, the world would have maybe locked Africa away. There would have been no emergency funding for vaccine development, limited global attention, and Africa would have become known as the continent of Covid.We may never know ...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Africa Coronavirus World news Science Source Type: news
CONCLUSIONS: In Saudi Arabia, Pfizer/BioNTech and Oxford/AstraZeneca vaccinations significantly reduced the number of SARS-CoV-2 cases and deaths after the vaccination compared to the period before the vaccination campaign at country levels. The study findings demonstrate that vaccination and adherence to nonpharmaceutical intervention can better control the COVID-19 pandemic.PMID:34859883 | DOI:10.26355/eurrev_202111_27271
Source: Pharmacological Reviews - Category: Drugs & Pharmacology Authors: Source Type: research
Eur Rev Med Pharmacol Sci. 2021 Nov;25(22):7162-7184. doi: 10.26355/eurrev_202111_27270.ABSTRACTThe last two decades have witnessed the emergence of three deadly coronaviruses (CoVs) in humans: severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There are still no reliable and efficient therapeutics to manage the devastating consequences of these CoVs. Of these, SARS-CoV-2, the cause of the currently ongoing coronavirus disease 2019 (COVID-19) pandemic, has posed great global health concerns. The...
Source: Pharmacological Reviews - Category: Drugs & Pharmacology Authors: Source Type: research
CONCLUSIONS: In Saudi Arabia, Pfizer/BioNTech and Oxford/AstraZeneca vaccinations significantly reduced the number of SARS-CoV-2 cases and deaths after the vaccination compared to the period before the vaccination campaign at country levels. The study findings demonstrate that vaccination and adherence to nonpharmaceutical intervention can better control the COVID-19 pandemic.PMID:34859883 | DOI:10.26355/eurrev_202111_27271
Source: Pharmacological Reviews - Category: Drugs & Pharmacology Authors: Source Type: research
Eur Rev Med Pharmacol Sci. 2021 Nov;25(22):7162-7184. doi: 10.26355/eurrev_202111_27270.ABSTRACTThe last two decades have witnessed the emergence of three deadly coronaviruses (CoVs) in humans: severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There are still no reliable and efficient therapeutics to manage the devastating consequences of these CoVs. Of these, SARS-CoV-2, the cause of the currently ongoing coronavirus disease 2019 (COVID-19) pandemic, has posed great global health concerns. The...
Source: Pharmacological Reviews - Category: Drugs & Pharmacology Authors: Source Type: research
CONCLUSIONS: In Saudi Arabia, Pfizer/BioNTech and Oxford/AstraZeneca vaccinations significantly reduced the number of SARS-CoV-2 cases and deaths after the vaccination compared to the period before the vaccination campaign at country levels. The study findings demonstrate that vaccination and adherence to nonpharmaceutical intervention can better control the COVID-19 pandemic.PMID:34859883 | DOI:10.26355/eurrev_202111_27271
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Authors: Source Type: research
Eur Rev Med Pharmacol Sci. 2021 Nov;25(22):7162-7184. doi: 10.26355/eurrev_202111_27270.ABSTRACTThe last two decades have witnessed the emergence of three deadly coronaviruses (CoVs) in humans: severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There are still no reliable and efficient therapeutics to manage the devastating consequences of these CoVs. Of these, SARS-CoV-2, the cause of the currently ongoing coronavirus disease 2019 (COVID-19) pandemic, has posed great global health concerns. The...
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Authors: Source Type: research
CONCLUSIONS: In Saudi Arabia, Pfizer/BioNTech and Oxford/AstraZeneca vaccinations significantly reduced the number of SARS-CoV-2 cases and deaths after the vaccination compared to the period before the vaccination campaign at country levels. The study findings demonstrate that vaccination and adherence to nonpharmaceutical intervention can better control the COVID-19 pandemic.PMID:34859883 | DOI:10.26355/eurrev_202111_27271
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Authors: Source Type: research
More News: Coronavirus | COVID-19 | Dentistry | Environmental Health | Health Management | History of Medicine | International Medicine & Public Health | Pandemics | Psychology | Respiratory Medicine | SARS | Vaccines